⚠ Scores are AI-generated estimates for informational purposes only — not investment advice. Data may be inaccurate or outdated. Do not make financial decisions based on this site. Full legal disclaimer →
⚠ Scores are AI-generated estimates for informational purposes only — not investment advice. Data may be inaccurate or outdated. Do not make financial decisions based on this site. Full legal disclaimer →
AI Exposure Analysis
Healthcare · Large Cap · Disruption threat: LOW
Moderna uses AI extensively in mRNA sequence design, clinical trial optimization, and drug discovery pipelines, with its 'mRNA OS' platform increasingly incorporating machine learning for candidate selection. AI is a core R&D enabler but does not yet directly drive revenue, keeping the overall score moderate.
Moderna is a large-cap biotechnology company specializing in mRNA therapeutics and vaccines. Based on its February 2026 SEC filing, the company earns an overall AI score of 46/100, reflecting meaningful but still-maturing AI integration across its operations, with commercial AI monetization remaining limited relative to its research applications. The score is anchored by moderate-to-solid marks in R&D AI Investment (60/100) and Product AI Integration (55/100), reflecting Moderna's deployment of machine learning across its mRNA OS platform for sequence and structure optimization, drug candidate screening, and clinical trial design and patient stratification. Internal AI Use (50/100) and AI Infrastructure (45/100) indicate operational adoption is progressing but not yet fully scaled. The low Revenue from AI score (10/100) confirms that AI remains a pipeline accelerator rather than a direct commercial driver. Moderna's LOW disruption threat rating is appropriate given that AI is enhancing rather than replacing its core competency. As an originator of AI-assisted drug design, the company is more likely to benefit from AI advances than be displaced by them, positioning it as a potential winner in the emerging era of computationally driven drug development. The key opportunity lies in converting R&D AI advantages into faster time-to-market and pipeline breadth. Execution risk centers on whether AI-designed candidates can sustain clinical success rates at scale.
Full interactive analysis at RankVis.io